Обзорная статья

Cancer classification using the Immunoscore: a worldwide task force

Jérôme GalonINSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F-75006, France. [email protected]Franck PagèsAssistance Publique-Hopitaux de Paris, HEGP, Paris, FranceFrancesco M. MarincolaInfectious Disease and Immunogenetics Section (IDIS), Clinical Center and trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Bethesda, Maryland, USAHelen K. AngellSorbonne UniversitéMagdalena ThurinCancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USAAlessandro LugliInstitute of Pathology, University of Bern, Bern, 3010, SwitzerlandInti ZlobecInstitute of Pathology, University of Bern, Bern, 3010, SwitzerlandAnne BergerAssistance Publique-Hopitaux de Paris, HEGP, Paris, FranceCarlo BifulcoDepartment of Pathology, Providence Portland Medical Center, Portland, OR, USAGerardo BottiDepartment of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G.Pascale", Naples, ItalyFabiana TatangeloDepartment of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G.Pascale", Naples, ItalyCedrik M. BrittenTRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, GermanySebastian KreiterTRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, GermanyLotfi ChouchaneWeill Cornell Medical College, Doha, QatarPaolo DelrioColorectal Surgery Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione G.Pascale", Naples, ItalyHartmann ArndtDepartment of Pathology, University of Erlangen, Erlangen, GermanyMartin AsslaberInstitute of Pathology, Medical University of Graz, Graz, AustriaMichele MaioDivision of Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, ItalyGiuseppe MasucciDepartment of Oncology-Pathology, Karolinska Institutet, Karolinska University, Stockholm, SwedenMartin MihmHarvard Medical School and Massachusetts General Hospital, Boston, MA, 02114-2696, USAFernando Vidal‐VanaclochaCEU-San Pablo University School of Medicine and HM-Hospital of Madrid Scientific Foundation, Institute of Applied Molecular Medicine (IMMA), Madrid, SpainJames P. AllisonLudwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY, USASacha GnjaticLudwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY, USALeif HåkanssonUniversity of Lund, Lund, SwedenChristoph HuberTRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, GermanyHarpreet Singh‐JasujaImmatics Biotechnologies GmbH, Tübingen, GermanyChristian H. OttensmeierExperimental Cancer Medicine Centre, University of Southampton Faculty of Medicine, Southampton, United KingdomH. ZwierzinaDepartment Haematology and Oncology, Innsbruck Medical University, Innsbruck, AustriaLuigi LaghiMolecular Gastroenterology and Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, ItalyFabio GrizziMolecular Gastroenterology and Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, ItalyPamela S. OhashiOntario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Hospital, University Health Network, Toronto, ON, CanadaPatricia A. ShawDepartments of Laboratory Medicine, Pathobiology & Radiation Oncology, Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, ON, CanadaBlaise ClarkeDepartments of Laboratory Medicine, Pathobiology & Radiation Oncology, Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, ON, CanadaBradly G. WoutersDepartments of Laboratory Medicine, Pathobiology & Radiation Oncology, Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, ON, CanadaYutaka KawakamiDivision of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, JapanShoichi HazamaDepartment of Digestive Surgery and Surgical Oncology, Yamaguchi University, Graduate School of Medicine, Yamaguchi, JapanKiyotaka OkunoDepartment of Surgery, Kinki University, School of Medicine, Osaka-sayama, JapanEna WangInfectious Disease and Immunogenetics Section (IDIS), Clinical Center and trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Bethesda, Maryland, USAJill O’Donnell-TormeyCancer Research Institute, New York, NY, USAChristine LagorceDepartment of Pathology, Avicenne Hospital, AP-HP, Bobigny, FranceGraham PawelecCenter for Medical Research, University of Tuebingen, Tuebingen, GermanyMichael I. NishimuraOncology Institute, Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL, USARobert D. HawkinsSchool of Cancer and Imaging Sciences, University of Manchester, Christie Hospital NHS Trust, Manchester, UKRéjean LapointeResearch Center, University Hospital, Université de Montréal (CRCHUM), Montréal, Québec, Canada ; Institut du Cancer de Montréal, Montréal, Québec, CanadaAndreas LundqvistKarolinska Institutet Department of Oncology-Pathology, Stockholm, SwedenSamir N. KhleifGeorgia Health Sciences University Cancer Center, Augusta, GA, USAShuji OginoDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAPeter GibbsDepartment of Medical Oncology, Royal Melbourne Hospital, Melbourne, AustraliaPaul WaringDepartment of Pathology, The University of Melbourne, Melbourne, AustraliaNoriyuki SatoDepartment of Pathology, Sapporo Medical University School of Medicine, Sapporo, JapanToshihiko TorigoeDepartment of Pathology, Sapporo Medical University School of Medicine, Sapporo, JapanKyogo ItohDepartment of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, JapanPrabhudas S. PatelThe Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, IndiaShilin N. ShuklaThe Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, IndiaRichard PalmqvistDepartment of Medical Biosciences, Pathology, Umea University, Umea, SwedenIrıs D. NagtegaalPathology Department, Radboud University Nijmegen Medical Center, Nijmegen, The NetherlandsYili WangInstitute for Cancer Research, Center of Translational medicine, Xi’an Jiaotong university, Xian, ChinaCorrado D’ArrigoDepartment of Histopathology, Dorset County Hospital, DCHFT, NHS, Dorchester, UKScott KopetzMD Anderson Cancer Center, Houston, TX, USAFrank A. SinicropeMayo Clinic and Mayo College of Medicine, Rochester, MN, 55905, USAGiorgio TrinchieriCancer Inflammation Program, Center for Cancer Research, National Cancer Institute and Trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Frederick and Bethesda, Maryland, USAThomas F. GajewskiSociety for Immunotherapy of Cancer, Milwaukee, WI, USAPaolo A. AsciertoFondazione Melanoma Onlus, Napoli, ItalyBernard A. FoxDepartment of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA

2012en

ABI

Аннотация

Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to incorporate the 'Immunoscore' into traditional classification, thus providing an essential prognostic and potentially predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This review represents a follow-up of the announcement of this initiative, and of the J Transl Med. editorial from January 2012. Immunophenotyping of tumors may provide crucial novel prognostic information. The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).

Перевод пока недоступен

Идентификаторы

DOI: 10.1186/1479-5876-10-205

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar